Fig. 2: Age affects the outcomes of gene therapy with an AAV-8-rh-3BNC117-IgG1-LS vector.

a–j, The AAV-8-rh-3BNC117-IgG1-LS vector was administered to rhesus macaques across four age groups: group 5 (a,b; 48 h, except for rh5-6 (see below)); group 6 (c,d; approximately 2 years); group 7 (e,f; 4 weeks); group 8 (g,h; 8 weeks); and group 9 (i,j; 12 weeks). LLOQ, lower limit of quantification. a,c,e,g,i, Serum rh-3BNC117-IgG1-LS concentrations. b,d,f,h,j, Anti-rh-3BNC117-IgG1-LS responses, or ADAs, in each group. k, Serum concentrations of rh-3BNC117-IgG1-LS at week 20 in the group 5 newborns (n = 5) and group 6 juveniles (n = 6). l, Comparison of cumulative levels of ADAs produced by the group 5 newborns and group 6 juveniles during the 20 weeks of follow-up. AUC, area under the curve. In k,l, the group 5 infant rh5-6 was not included in the comparisons because it received the AAV-8-rh-3BNC117-IgG1-LS vector 4 weeks after birth. m, Monkeys in groups 3 and 5–9 were divided into three age brackets and their serum rh-3BNC117-IgG1-LS concentrations at week 20 were compared. In k–m, bars correspond to medians and P values were two-sided and calculated using the Mann–Whitney U-test. P values in brackets were calculated without the group 6 outlier rh6-6. n, Correlation between the age (in weeks) of each monkey at the time of AAV inoculation and serum rh-3BNC117-IgG1-LS concentration at week 20.

Source Data